http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30404153

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage 8
issn 0920-1211
pageRange 1-8
publicationName Epilepsy Research
startingPage 1
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_eb18fe99130b8e9bb1f6902cafe0f49f
bibliographicCitation Krauss G, Biton V, Harvey JH, Elger C, Trinka E, Soares da Silva P, Gama H, Cheng H, Grinnell T, Blum D. Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials. Epilepsy Res. 2018 Jan;139():1–8. doi: 10.1016/j.eplepsyres.2017.10.021. PMID: 29127848.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e7c22cd367fd0df9af91737e0ddc1e57
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2399439874d692f23c5b4ecb9cbc89e3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16937b02f0361bc66a1c99ea719f248a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0bd53662228bca0eb4838701569199c8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-5950-2692
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5606d45824ece4e9c1521b0b0295580c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e91d101942fe3715f2289db02d52384a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8afc91e191b90e6297f3e9b698476e4b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_75848ff6676f396de19193865a9c8441
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_942e085883e4bb05aa3b88af71526dce
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ce4ff55fcc11e539dc33465564bcaba
date 201801
identifier https://doi.org/10.1016/j.eplepsyres.2017.10.021
https://pubmed.ncbi.nlm.nih.gov/29127848
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3587
https://portal.issn.org/resource/ISSN/0920-1211
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials
discusses http://id.nlm.nih.gov/mesh/M0006249
http://id.nlm.nih.gov/mesh/M0001382
http://id.nlm.nih.gov/mesh/M0374531
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D000927Q000008
http://id.nlm.nih.gov/mesh/D000927Q000009
http://id.nlm.nih.gov/mesh/D003984Q000008
http://id.nlm.nih.gov/mesh/D012640Q000188
http://id.nlm.nih.gov/mesh/D003984Q000009
hasSubjectTerm http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D004305
http://id.nlm.nih.gov/mesh/D055118
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D000069279Q000188
http://id.nlm.nih.gov/mesh/D004334
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D004311
http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D017024
http://id.nlm.nih.gov/mesh/D016896
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6654
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7483
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7907
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9191
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID179344

Total number of triples: 53.